Clover Health Just Hit Profitability — Here's What the Headlines Missed

Añadido: 2026-05-13

[00:00:01]Welcome back. This is going to be a great video. I'm really excited about this. Today, we're conducting a fundamental audit on Clover Health's Q1 2026 results.

[00:00:13]For years, Clover uh the Clover thesis was a story stock, uh a promise that software could outperform legacy insurance models.

[00:00:31]And yesterday's earnings, that story became a testable financial real uh reality.

[00:00:38]We saw the first quarterly gap net income in company history at $27 million.

[00:00:45]Revenue growth of 62% and a cash position that jumped from 78 million to 173 million in 90 days.

[00:00:57]The existential survival question, I would say with 98% certainty, is off the table.

[00:01:05]But as serious analysts, we don't shear the headline. We audit the data. Today, we peel back the accounting to see if this profit is a sustainable inflection or a collection of one-time tailwinds.

[00:01:26]The bull case starts with operating leverage. Revenue surged 62% but adjusted SGNA dropped from 18% to under 16 of revenue while legacy giants like United Health and CVS are retreating from markets.

[00:01:44]Clover expanded its membership by 51% to over 155,000 lives by maint and while maintaining stable benefits.

[00:02:02]But let's get precise in the cohort math. A new Clover member still represents a contribution loss of about $145 per member per month in their first year. However, returning members who have been in the Clover Assistant ecosystem longer are generating roughly $200 per member per month in contribution profit. More importantly, the gross profit gap between a year 1 and year three cohort widens by $155 per member per month as those members mature.

[00:02:38]This is the secret sauce. If Clover can continue to layer these high margin older cohorts under its new growth, the model finally scales.

[00:02:53]There is a massive regulatory shift happening in Medicare Advantage and Clover is leaning into it. They currently hold the number one national PO ranking on heat quality at 4.72.

[00:03:08]But you have to be careful with the star rating terminology.

[00:03:12]Clover earned four stars for the 2026 payment year. That's the bonus money hitting the P&L right now. However, for the 2027 payment year, the overall PO rating um the CMS rating is uh 3.5 stars.

[00:03:33]Until we hear more on the lawsuit between CMS and Glover Health, it's up in the air. 2027 could be 35 or it could go up to four.

[00:03:48]While their clinical quality remains top tier, the slight dip in overall rating is a variable we need to model for the 2027 revenue.

[00:03:59]Quality is the moat, but the regulatory goalposts are always moving.

[00:04:10]This is where we get clinical. Clover reported a 29 million yearover-year swing of to profitability.

[00:04:19]But look at the stockbased compensation.

[00:04:23]Lake management has told us it would and has gone down dramatically. Stockbased compensation dropped from 26.4 million to 12.3 million.

[00:04:34]That $14 million reduction uh while a real improvement in expense management accounts for nearly half of the entire year-over-year profit swing.

[00:04:48]This isn't just core operating magic.

[00:04:50]It's a massive non-cash tailwind if they continue to mitigate stock uh stockbased compensation.

[00:05:04]Now, let's audit the $18 million in operating cash flow. On the surface, it's a monster number, but look at the working capital. It was heavily supported by a 107 million lift in unpaid claims reserves. Money Clover has uh money that Clover has set aside for medical bills, it hasn't actually cut checks for yet.

[00:05:31]This was partially offset by a $65 million headwind in acred retrospective premiums. But the net result is clear.

[00:05:40]Cash flow was flattered by uh accounting timing.

[00:05:46]If medical claims develop even slightly higher than the estimated in uh the estimated in Q2, this tailwind reverses potentially violently.

[00:06:07]Then we have the yellow flags. Clay Thornton is labeled uh as interimm CFO as we had expected because this is a relatively fresh fresh development.

[00:06:20]However, changing financial leadership during the most pivotal year in company history is a very real risk.

[00:06:28]Furthermore, dilution is still a potential factor. The diluted share count grew 7% year-over-year to 532 million shares, even with gap profits.

[00:06:41]Your slice of the pie is getting smaller. Let's continue to observe and see if this slows down.

[00:06:55]Finally, look at the guidance.

[00:06:57]management is guiding for 0 to 20 million in net income for the full year in line with their original guidance.

[00:07:05]Since they already printed 27 million in Q1, the math implies that Q2 through Q4 could collectively collectively see a net loss of 7 million or more unless we raise fullear guidance.

[00:07:20]Understanding that they guide very conservatively, I would not be surprised to see a raise to 5 to 25 million for fullear gap net income, but that's speculative on my part, and none of this is financial advice.

[00:07:38]Some of this is standard Medicare Advantage seasonality. Q1 is often the high water mark due to risk adjustment timing, but it suggests the inflection might plateau for the rest of 2026.

[00:07:51]We will have to wait and see.

[00:07:59]What is Clover actually worth?

[00:08:02]Uh, as a pure play subscale Medicare Advantage insurer, it trades in line with its smaller peers. But the bull case is predicated on a valuation rerating to an AI SAS multiple through counterpart health.

[00:08:17]Management claims a 450% increase in counterpart users, which is excellent for the narrative, but we still have zero revenue breakout. Until there is a disclosed revenue line for the software, you will simply you're you are simply underwriting a story, not a fundamental certainty yet.

[00:08:41]Um, why pay for a SAS multiple?

[00:08:47]You know, I won't pay for a SAS multiple until I see the revenue. Um, luckily we're really far away from SAS multiples at this time. So, I think I'm gonna continue buying.

[00:09:08]Q1 2026 is a milestone, but not a mission accomplished moment. The survival question is gone, but the steadystate margin question still remains.

[00:09:28]For me to stay constructive, I'm watching these four things in Q2.

[00:09:34]Beer stability. Can they keep it under 87% with new member influx?

[00:09:40]Um news on a permanent CFO hire. It may take much longer than a quarter or two to determine a new CFO, but we need to be we need some stable permanent leadership.

[00:09:57]Um, counterpart revenue. This one is a take it or leave it. It would be great to see this, but honestly, I don't expect this until next year, maybe even 2028.

[00:10:09]Um, and the 2027 star uh star ratings, how do they regain that 4.0 star overall rating with the lawsuit?

[00:10:20]Uh, they may regain the half star for 2027, but we should be wary if CMS might wrongfully judge Clover again for the 2028 star ratings. Time will tell. Until then, stay disciplined and continue to educate yourself. Before you go, if you want to institutionalize your research process, consider securing lifetime access to also trades.

[00:10:51]Founded by Dr. Albert Allen, the platform gives you permanent uninterrupted access to over 60 advanced analytical tools and more than 40 years of historical data.

[00:11:04]All without any necessary reoccurring subscription fees.

[00:11:08]To lock in this long-term value, click the link in my description down below.

[00:11:14]Use code dragon at checkout and take a massive $2,300 off your lifetime membership.

[00:11:23]Replace market speculation with objective data driven conviction today.

[00:11:29]I'll see you in the next video.